NLS Pharmaceutics CEO Issues Letter To Shareholders
NLS Pharmaceutics CEO Issues Letter To Shareholders
NLS 製藥公司首席執行官向股東發出信
NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announces that its Chief Executive Officer, Alex Zwyer, has issued the following letter to shareholders:
致力於發現和開發治療罕見和複雜中樞神經系統疾病患者的創新療法的瑞士臨牀期生物製藥公司NLS製藥有限公司(納斯達克代碼：NLSP)(納斯達克代碼：NLSPW)(以下簡稱“NLS”或“公司”)今天宣佈，其首席執行官亞歷克斯·茲懷爾已致信股東如下：
To our Shareholders and Friends,
致我們的股東和朋友：
Just under two years ago, NLS Pharmaceutics sought your investment and support to advance our pipeline in rare sleep disorders and other rare and debilitating Central Nervous System disorders. I am pleased to report on the progress that we made towards building a...
就在不到兩年前，NLS製藥公司尋求您的投資和支持，以推進我們治療罕見睡眠障礙和其他罕見...
登入免費觀看全文
登入/註冊